SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of hands with thumbs up in a row, radiating positivity and consensus in bright tones on a clean background
Approvals
AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer
Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.
May 28, 2026
 · 
1 min read
 · 
Tristan Manalac
Insights
France’s biotech ecosystem: science, capital and scale
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.
May 28, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Photo of panoramic view of New Jersey City skyline
Job Trends
11 companies hiring in New Jersey now
Looking for a biopharma job in New Jersey? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
May 28, 2026
 · 
2 min read
 · 
Angela Gabriel
Illustration showing two businessmen negotiating with big speech bubbles next to each other
Career Advice
Should biopharma professionals negotiate job offers in an employer’s market?
Three experts discuss whether biotech and pharma professionals should try to convince employers to adjust employment offers, mistakes people make during the process and tips for getting it right.
May 28, 2026
 · 
6 min read
 · 
Angela Gabriel
Tumor with increased vascularisation
Opinion
The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
May 28, 2026
 · 
6 min read
 · 
Souro Chowdhury
Find Business Growth Opportunity, Business Standing Analyzing Arrow Gate
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
May 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Customer feedback giving rating based on experience or quality from product and service, survey, opinion and review to evaluate result, man trying to push customer feedback bar to be excellent smile.
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
May 27, 2026
 · 
3 min read
 · 
Annalee Armstrong
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
May 27, 2026
 · 
2 min read
 · 
Annalee Armstrong
IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch
IPO tracker
Kardigan cozies up to public markets to support heart disease drugs
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
May 27, 2026
 · 
14 min read
 · 
Editorial Team
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS